24/7 Wall Street
12 Jun 2026, 11:35 UTC · 1h ago
The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
12 Jun 2026, 11:35 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Vertex Pharmaceuticals' povetacicept BLA for IgA nephropathy is currently under a six-month FDA Priority Review. — Regulatory approvals for new drug indications are high-impact binary catalysts that typically drive significant stock price movement.
+0.60Hershey reaffirmed its FY2026 adjusted EPS guidance of $8.20 to $8.52, implying low-double-digit growth. — Reaffirmed positive guidance provides a fundamental floor for the stock and supports bullish analyst price targets.
+0.40Vertex Pharmaceuticals reported Q1 2026 non-GAAP EPS of $4.47, beating estimates and seeing operating income rise 80.62% year over year. — Strong earnings growth and operating leverage validate the company's diversification thesis and fundamental strength.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Both Hershey and Vertex Pharmaceuticals have triggered 'death cross' technical signals, though the gap between their 50-day and 200-day moving averages is minimal. — While technically bearish, the article argues the signal is 'mechanically valid but informationally weak,' limiting its downward pressure.
-0.20Which stocks this story touches
Strong earnings momentum, significant cash growth, and a pending FDA priority review for a new drug catalyst.
Despite a 'death cross' technical signal, the company had a Q1 earnings beat and reaffirmed positive full-year guidance.
Mentioned only as a historical reference for an analyst's previous success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
41m ago
